Ionis Pharmaceuticals (IONS) Other Non-Current Assets (2009 - 2026)
Ionis Pharmaceuticals (IONS) posted quarterly Other Non-Current Assets of $116.5 million for Q2 2026, down 11.78% year-over-year from $132.1 million in Q2 2025, and down 14.03% quarter-over-quarter from $135.6 million in Q1 2026.
Ionis Pharmaceuticals (IONS) Other Non-Current Assets (2009 - 2026) Analysis & Trends
Ionis Pharmaceuticals' Other Non-Current Assets history runs 18 years deep, the most recent figure standing at $116.5 million for Q2 2026.
- In Q2 2026, Other Non-Current Assets fell 11.78% year-over-year to $116.5 million; the TTM figure through Jun 2026 stood at $116.5 million (down 11.78% YoY), while the FY2025 annual figure was $171.6 million, up 34.83% from the prior year.
- Other Non-Current Assets for Q2 2026 stood at $116.5 million, down from $135.6 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $171.6 million in Q4 2025, with the low at $58.9 million in Q2 2022.
- The 5-year median for Other Non-Current Assets is $111.3 million (2024), against an average of $108.5 million.
- The sharpest annual moves came in 2023 and 2026: Other Non-Current Assets surged 75.12% in 2023, then decreased 11.78% in 2026.
- Ionis Pharmaceuticals' Other Non-Current Assets stood at $75.3 million in 2022, then jumped by 39.73% to $105.3 million in 2023, then gained by 20.89% to $127.3 million in 2024, then surged by 34.83% to $171.6 million in 2025, then slumped by 32.09% to $116.5 million in 2026.
- Business Quant data shows IONS's Other Non-Current Assets at $116.5 million in Q2 2026, $135.6 million in Q1 2026, and $171.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Ionis Pharmaceuticals | 9.48 Bn | 7.43 Bn | 265.21 Mn | 116.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 116.54 Mn |
| Mar 31, 2026 | 135.56 Mn |
| Dec 31, 2025 | 171.60 Mn |
| Sep 30, 2025 | 165.99 Mn |
| Jun 30, 2025 | 132.10 Mn |
| Mar 31, 2025 | 131.82 Mn |
| Dec 31, 2024 | 127.28 Mn |
| Sep 30, 2024 | 120.32 Mn |
| Jun 30, 2024 | 118.90 Mn |
| Mar 31, 2024 | 106.03 Mn |
| Dec 31, 2023 | 105.28 Mn |
| Sep 30, 2023 | 104.08 Mn |
| Jun 30, 2023 | 86.03 Mn |
| Mar 31, 2023 | 78.30 Mn |
| Dec 31, 2022 | 75.34 Mn |
| Sep 30, 2022 | 59.43 Mn |
| Jun 30, 2022 | 58.92 Mn |
| Mar 31, 2022 | 58.95 Mn |
| Dec 31, 2021 | 70.60 Mn |
| Sep 30, 2021 | 48.97 Mn |